Core Viewpoint - The announcement highlights that Zhifei Biological's subsidiary, Zhifei Longkema, has received the clinical trial application acceptance notice from the National Medical Products Administration for its recombinant herpes zoster vaccine ZFA01, which utilizes a novel adjuvant to enhance immune responses [1] Company Summary - Zhifei Biological's subsidiary, Zhifei Longkema, is developing the recombinant herpes zoster vaccine ZFA01 [1] - The vaccine is designed to prevent diseases caused by herpes zoster infection [1] - The new adjuvant developed by the company aims to stimulate both cellular and humoral immune responses, potentially improving the vaccine's protective efficacy [1] Industry Summary - The vaccine development is part of the broader pharmaceutical industry efforts to enhance vaccine effectiveness through innovative adjuvants [1] - The acceptance of the clinical trial application indicates progress in the regulatory pathway for new vaccine candidates in the market [1]

智通财经APP讯，智飞生物(300122.SZ)公告，公司全资子公司安徽智飞龙科马生物制药有限公司(简 称"智飞龙科马")研发的重组带状疱疹ZFA01佐剂疫苗(CHO细胞)获得国家药品监督管理局药物临床试验 申请受理通知书。自受理之日起60日内，未收到药审中心否定或质疑意见的，智飞龙科马可以按照提交 的方案开展临床试验。 ...